opnMe

Cardiometabolic chronic kidney disease (CM-CKD) shows highly heterogeneous disease progression. Growing evidence points to diverse underlying mechanisms that can lead to similar clinical presentations despite differences in cardiovascular risk and treatment responses. How would you propose to identify and validate novel non-invasive, mechanism-anchored biomarkers linking kidney biology to cardiovascular risk in CM-CKD? Submit your ideas on #opnMe for a chance to access funding: https://lnkd.in/ef_wQ8SV

Cardiometabolic chronic kidney disease (CM-CKD) shows highly heterogeneous disease progression. Growing evidence points to diverse underlying mechanisms that can lead to similar clinical presentations despite differences in cardiovascular risk and treatment responses. How would you propose to identify and validate novel non-invasive, mechanism-anchored biomarkers linking kidney biology to cardiovascular risk in CM-CKD? Submit your ideas on #opnMe for a chance to access funding: https://lnkd.in/exedsBmD

Cardiometabolic chronic kidney disease (CM-CKD) is the largest and fastest-growing form of CKD worldwide. Clinical decision making and drug development rely largely on estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, which do not fully reflect the biology underlying disease progression and cardiovascular risk. To support the development of mechanism-targeted therapies, we invite proposals for non-invasive biomarkers linking kidney biology to cardiovascular risk in CM-CKD. Learn more on #opnMe: https://lnkd.in/eZDxRGxJ

Cardiometabolic chronic kidney disease (CM-CKD) is the largest and fastest-growing form of CKD worldwide. Clinical decision making and drug development rely largely on estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, which do not fully reflect the biology underlying disease progression and cardiovascular risk. To support the development of mechanism-targeted therapies, we invite proposals for non-invasive biomarkers linking kidney biology to cardiovascular risk in CM-CKD. Learn more on #opnMe: https://lnkd.in/ejHTHBkj

In synthetic chemistry, systematic reaction scope data across different methodologies can help assess their real-world applicability and support future predictive models for synthesis planning. To generate such datasets, we invite academic researchers developing innovative synthetic transformations, catalysts or synthesis technologies to challenge their chemistry against 96 pharma-relevant aryl bromides, evaluated free of charge by scientists at Boehringer Ingelheim. Ready to test your methodology? Get started on #opnMe:https://lnkd.in/eeqjmscD

In synthetic chemistry, systematic reaction scope data across different methodologies can help assess their real-world applicability and support future predictive models for synthesis planning. To generate such datasets, we invite academic researchers developing innovative synthetic transformations, catalysts or synthesis technologies to challenge their chemistry against 96 pharma-relevant aryl bromides, evaluated free of charge by scientists at Boehringer Ingelheim. Ready to test your methodology? Get started on #opnMe: https://lnkd.in/eqWGwq_C